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D

ecreased expression of speciﬁc microRNAs (miRNAs) occurs in human tumors, which suggests a
function for miRNAs in tumor suppression. Herein,
levels of the miR-17-5p/miR-20a miRNA cluster were inversely correlated to cyclin D1 abundance in human breast
tumors and cell lines. MiR-17/20 suppressed breast cancer cell proliferation and tumor colony formation by negatively regulating cyclin D1 translation via a conserved 3⬘
untranslated region miRNA-binding site, thereby inhibiting serum-induced S phase entry. The cell cycle effect

of miR-17/20 was abrogated by cyclin D1 siRNA and in
cyclin D1–deﬁcient breast cancer cells. Mammary epithelial cell–targeted cyclin D1 expression induced miR-17-5p
and miR-20a expression in vivo, and cyclin D1 bound the
miR-17/20 cluster promoter regulatory region. In summary,
these studies identify a novel cyclin D1/miR-17/20 regulatory feedback loop through which cyclin D1 induces
miR-17-5p/miR-20a. In turn, miR-17/20 limits the proliferative function of cyclin D1, thus linking expression of a
speciﬁc miRNA cluster to the regulation of oncogenesis.

Introduction
MicroRNAs (miRNAs) are 21–22 nucleotide molecules that
regulate the stability or translational efficiency of targeted
mRNAs. Derived from nuclear precursor RNAs, initial processing occurs by the internuclease Drosha to release pre-miRNAs
of 60–70 nucleotides in length from pri-miRNA. Subsequent
transport to the cytoplasm by exportin-5 results in processing
by the internuclease Dicer to generate the ⵑ22-nucleotide mature miRNA (Yi et al., 2003; Lund et al., 2004; Zhang et al.,
2004). The base pairing interactions between miRNAs and their
target mRNAs, often within the 3⬘ untranslated region (UTR)
of target genes, results in the degradation of target mRNAs
(Ambros, 2004; Cullen, 2004) or inhibition of their translation
(Lai, 2002). To date, 533 miRNAs have been identified in humans
(miRBase Sequence Database version 10.0, released in August
2007; http://microrna.sanger.ac.uk/sequences/). It has been proposed that, as each vertebrate miRNA may bind to as many as
200 gene targets, miRNAs potentially control the expression of
about one-third of human mRNAs (Krek et al., 2005).

Several independent lines of evidence support a role for
miRNAs in human cancer (Calin et al., 2005; Croce and Calin,
2005, 2006; He et al., 2005, 2007). miRNA-encoding genes are
frequently located at fragile sites, as well as in minimal regions
of loss of heterozygosity, minimal regions of amplification,
and in common breakpoint regions involved in cancers (Calin
et al., 2004). Aberrant expression of miRNAs or mutations of
miRNA genes have been described in many types of tumors.
Let-7 abundance is reduced in several cancers, including lung
cancer (Takamizawa et al., 2004), and let-7 was reported to
regulate tumor growth by targeting the ras gene (Johnson et al.,
2005). miR-15a and miR16-1 were deleted and/or downregulated in ⵑ70% of patients with chronic lymphocytic leukemia (Calin et al., 2002). miR-15a/16-1 induced apoptosis by
inhibiting BCL-2 (Cimmino et al., 2005). The miR-34 family is
an important component of the p53 tumor suppressor network
(He et al., 2007). The human miR-17/20 cluster’s genomic
location, chromosome 13q31, correlates with loss of heterozygosity in several different cancers, including breast cancer
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Results
miR-17/20 down-regulates cyclin D1
expression and suppresses breast cancer
cell proliferation

The miR-17/20 cluster located on chromosome 13q31 encodes
six miRNAs within an ⵑ1-kb region. Amplification and overexpression of miR-17/20 has been described in B cell lymphomas
(He et al., 2005) and lung cancers (Hayashita et al., 2005).
miR-17-5p and miR-20a are key important components of the
miR-17/20 cluster. To characterize the miR-17/20 expression
in breast cancer cell lines, Northern blot analysis was performed
of nine breast cancer cell lines (MDA-MB-231, BT-474, MDAMB-453, Hs578T, MDA-MB-486, SKBR-3, MDA-MB-361,
510
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Figure 1. miR-17/20 inhibits breast cancer cell proliferation. (A) The genomic region of miR-17/20 cluster on chromosome 13q31 and the vector
structure for miRNA17/20 overexpression. (B) Northern blot analysis
demonstrating the increased expression of the six members of miR-17/20
cluster in the miR-17/20–transduced MCF-7 cells. tRNA served as loading
control. (C and D) Cellular proliferation assay; (E) an MTT assay; and
(F) a colony formation assay consistently showed the inhibition of MCF-7
cell proliferation by miR-17/20 overexpression. Cellular proliferation assays and the MTT assay were performed in three independent experiments
(data are equal to mean ± SEM). *, P < 0.01.

MCF-7, and T-47D), one nontumorigenic breast epithelial cell
line (MCF-10A), and two nonbreast tumor cell lines (HeLa and
293T; Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200801079/DC1). The expression of miR-17-5p and miR-20a
was low to undetectable in at least six of the nine breast cancer
cell lines compared with either nontumorigenic breast epithelial
cell (MCF-10A) or nonbreast cancer cell lines (HeLa and 293T).
The reduced expression of miR-17/20 in breast cancer cells
suggested the miRNA cluster may have a unique function during breast tumorigenesis.
To further investigate the role of miR-17/20 in breast cancer, a retroviral vector encoding the miR-17/20 cluster was used
to infect MCF-7 and the NAFA cell line, which is derived from
MMTV-ErbB2 transgenic mice breast tumors (Fig. 1 A). Northern blotting confirmed the increased expression of the components in the miR-17/20 cluster (miR-17-5p, 18a, 19a, 19b, 20a,
and 92) in the transduced cells (Fig. 1 B). Cellular proliferation
assays were performed on the miR-17/20–transduced cells.
miR-17/20 expression inhibited MCF-7 cell proliferation and
cell growth by ⵑ60% after 72 h (Fig. 1, C and D). To determine
if miR-17/20 regulated estrogen-dependent cellular proliferation, MCF-7 cells were treated with estrogen (17␤-estradiol).
Both estrogen-dependent and -independent cell proliferation
was inhibited by miR-17/20 (Fig. 1 E). Furthermore, miR-17/20
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(Eiriksdottir et al., 1998; Lin et al., 1999). The expression and
function of miRNA varies by cell type. The miR-17/20 cluster functions as a tumor suppressor in the human B cell line
P493-6 by decreasing E2F1 expression, thereby inhibiting mycinduced cell proliferation (O’Donnell et al., 2005). In contrast,
in both lung cancer and lymphomas, expression of this miRNA
cluster was increased, enhancing cell growth (Hayashita et al.,
2005; He et al., 2005). As the same miRNA performs different functions through distinct pathways dependent on the
tissue or cell type, it is important to understand the mechanisms by which miRNA regulates the cell cycle and thereby
tumorigenesis.
The onset and progression of tumorigenesis involves evasion of apoptotic signals, sustained cellular proliferation, and
the ability to promote tumor neoangiogenesis. Cyclin D1 overexpression is found in ⵑ50% of human breast cancers (Fu et al.,
2004). Antisense to cyclin D1 abrogated the growth of ErbB2induced breast tumors, and cyclin D1⫺/⫺ mice are resistant to the
induction of tumors either in the mammary gland or the skin induced by oncogenic ras or ErbB2 (Lee et al., 2000; Fu et al., 2004).
A subset of miRNAs are regulated by oncogenic myc and ras
(Johnson et al., 2005; O’Donnell et al., 2005), but the requirement for cell cycle proteins in the regulation of miRNA is still
unknown. Furthermore, the understanding of the mechanism by
which specific oncogenes regulate miRNA expression and function is limited.
By a large-scale miRnome analysis using miRNA chips on
mouse mammary tumor virus (MMTV)–cyclin D1 transgenic
mice and cyclin D1 knockout mice, we determined a subset of
miRNAs controlled by cyclin D1. These studies identified a novel
regulatory mechanism in which cyclin D1 induces a miRNA
signature that includes miR-17-5p and miR-20a through the
binding of the miR-17/20 promoter region. miR-17/20 in turn
attenuates cyclin D1 abundance via a negative feedback loop to
regulate cyclin D1 through a conserved 3⬘ UTR miRNA binding
site. Given the central role for cyclin D1 in cellular differentiation and tumorigenesis, the studies herein, which demonstrate
that miRNAs determine cyclin D1 abundance, have broad implications for cancer biology. This work demonstrates additional
regulatory mechanisms between oncogenes and tumor suppressor miRNAs that act in concert with other factors to limit oncogene function.

Published August 11, 2008

inhibited MCF-7 contact-independent growth determined through
colony formation assays (Fig. 1 F).
miR-17/20 arrests the cell cycle at the G1
phase in a cyclin D1–dependent manner
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To determine the mechanism by which miR-17/20 suppressed
breast cancer cell proliferation, the abundance of key cell cycle
regulatory proteins was assessed. Cyclin D1 abundance is rate
limiting for MCF-7 cell DNA synthesis. Cyclin D1 expression
was inhibited ⵑ50% by miR-17/20 overexpression, whereas
cyclin E, Cdk 4, and Cdk 6 expressions were unaltered in miR17/20–transduced cells (Fig. 2 A).
To examine the functional interrelationship between
miR-17/20 and cyclin D1, cyclin D1 siRNA was used to transfect miR-17/20–transduced MCF-7 cells (Fig. 2 B). miR-17/20–
transduced MCF-7 cells were starved with 5% charcoal-stripped
serum for 48 h, and cellular DNA synthesis was stimulated by
the addition of 10% normal FBS. Cell cycle analysis was conducted before serum stimulation and upon 16 h of serum treatment. The proportion of cells corresponding to the proportion of
cells in the S and G2/M phase was lower in miR-17/20–transduced
MCF-7 cells (25.9 ± 0.6% vs. 9.9 ± 0.3%) than that in control
cells (31.1 ± 0.4% vs. 14.9 ± 0.8%; Fig. 2 C). The G0/G1 phase was
increased in miR-17/20–transduced MCF-7 cells (62.4 ± 0.6%)
compared with control cells (51.8 ± 0.1%). The inhibition of
S phase by miR-17/20 was dependent on cyclin D1, as cyclin
D1 knockdown with siRNA abrogated the G1 phase and S phase
differences between miR-17/20 overexpressed MCF-7 cells
(G0/G1: 67.5% ± 0.7%; S, 14.8 ± 1.0%) and control cells (G0/G1:
68.8% ± 0.5%; S, 14.4 ± 0.6%; Fig. 2 C).
MCF-7 cells express abundant cyclin D1. In contrast with
MCF-7 cells, transduction of MCF-10A and BT-474 cells, which
have low abundance of cyclin D1 (Fig. 3), with the miR-17/20
cluster had no demonstratable effect on DNA synthesis induced
by FBS (Fig. S2, available at http://www.jcb.org/cgi/content/full/
jcb.200801079/DC1). These results indicate that the inhibition
of G1/S transition by miR-17/20 is cyclin D1 dependent.
The ErbB2 oncogene is overexpressed or amplified in
ⵑ30% of human breast cancers and is sufficient for mammary
tumor generation when targeted to the mammary gland in transgenic mice. The NAFA cell line is derived from MMTV-ErbB2
transgenic tumors. To determine the role of miR-17/20 cluster
in ErbB2-mediated tumor growth, the NAFA cell line was transduced with the expression vector encoding an miR-17/20 cluster (Fig. 1 A). The expression of miR-17-5p and miR-20a was
induced in NAFA cells transduced with the miRNA17/20 cluster (Fig. 2 D). miR-17/20 expression inhibited proliferation of
NAFA cells (Fig. 2 E).
To examine further the specificity with which miR-17/20
inhibits cyclin D1 abundance, chemically modified miRNA
inhibitors (anti-mir) were used to block miRNA function.
The miR-17/20 locus–transduced MCF-7 cells were transfected
with anti–miR-17-5p and anti–miR-20a, which can specifically interact with miR-17-5p and miR-20a, respectively, to block their
function. Cyclin D1 abundance is rate-limiting in MCF-7 cells
for DNA synthesis and cell proliferation. Both anti–miR-17-5p
and anti–miR-20a rescued the inhibition of cyclin D1 abundance

Figure 2. miR-17/20 arrests cell cycle at the G1 phase in a cyclin D1–
dependent manner. (A) Western blot analysis of the cyclin D1, CDK4,
CDK6, and cyclin E expression in miR-17/20–transduced cells. GDI
served as loading control. (B) MCF-7 cells were transfected with cyclin
D1 siRNA and control siRNA. Western blotting demonstrated the efﬁcient
knockdown of cyclin D1 after 72 h of siRNA treatment. (C) Cell cycle
analysis indicated the increased population of cells at G0/G1 phase and
decreased S and G2/M phase cells in miR-17/20–transduced MCF-7 cells
under a cyclin D1 background. This difference was abolished by knockdown
of cyclin D1 in cells. The analysis was performed in triplicates (data
are equal to mean ± SEM). (D) Northern blot demonstrated the increased
expression of miR-17/20 in the miR-17/20–transduced NAFA cells.
tRNA served as a loading control. (E) The MTT assay showed the inhibited
cell proliferation of NAFA cells by miR-17/20 transduction. The assay
was performed in three independent experiments, and the data are presented as the mean ± SEM.

by miR-17/20 (Fig. 3 A). Both anti-mirs reversed the antiproliferative function of miR-17/20 (Fig. 3 B), which is consistent with
the functional role of cyclin D1. The abundance of AIB1, a target
of miR-17-5p repression, was inhibited as previously described
by miR-17/20 (Hossain et al., 2006). The down-regulation of
cyclin D1 and AIB1 by miR-17/20 could be rescued by either
anti–miR-17-5p or anti–miR-20a (Fig. 3 A).
To determine whether endogenous miR-17/20 regulates
cyclin D1 abundance and cell proliferation, MCF-7 cells were
transfected with anti–miR-17-5p and anti–miR-20a. Inhibition of
these endogenous miRNAs’ function enhanced cellular proliferation and cyclin D1 abundance (Fig. S3, available at http://
www.jcb.org/cgi/content/full/jcb.200801079/DC1).
CYCLIN D1/MICRORNA 17/20 REGULATORY LOOP • Yu et al.
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Cyclin D1 is rate-limiting in tumorigenesis induced by
several breast oncogenes (Ras, Src, and ErbB2; Fu et al., 2004).
In view of the finding that cyclin D1 level was reduced by
miR-17/20 expression, we examined the relative abundance of
cyclin D1 and miR-17/20 in 11 different human cell lines and 16
matched normal and tumorous human breast samples. The abundance of cyclin D1 and expression of miR-17/20 were inversely
correlated (Fig. 3, C and D). Statistical analysis showed significant
down-regulation of miR-17/20 expression in breast tumors over
matching normal tissue (Fig. 3 E), and significant up-regulation
of cyclin D1 expression in breast tumors over matching normal
tissue (Fig. 3 F). There is a significant association between the
up-regulation of expression in cyclin D1 and the down-regulation
of miR-17/20 expression (Fig. 3 G)
miR-17/20 represses cyclin D1 through
a conserved 3ⴕ UTR binding site

To determine the mechanism by which miR-17/20 inhibited
cyclin D1 abundance, quantitative real-time PCR analysis was
512
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Figure 3. The inverse correlation between cyclin D1
abundance and miR-17/20 expression in human breast
cancer tissues and cell lines. (A) Western blots showed
the repression of cyclin D1 and AIB1 abundance by
miR-17/20. Both anti–miR-17-5p and anti–miR-20a
increased the expression of cyclin D1 and AIB1 in cells.
AIB1 is a positive control. ␤-tubulin was a loading control.
(B) Cotransfection of anti–miR-17-5p or anti–miR-20a
reversed the antiproliferative function of miR-17/20 in
MCF-7 cells. (C) Western blots showed the high cyclin
D1 level in low miR-17/20–expressing breast cancer
cell lines, and low cyclin D1 in high miR-17/20 cell
lines. A Northern blot of miRNA17/20 is shown in
Fig. S1 (available at http://www.jcb.org/cgi/content/
full/jcb.200801079/DC1). (D) The abundances
of cyclin D1 and miR-17-5p/miR-20a in 16 human
breast tumor tissues and 16 matching normal breast
tissues were determined by Western and Northern
blots. Tissue sample IDs were provided by the sample
provider. Black lines indicate that intervening lanes
have been spliced out. N, normal tissue; T, tumor tissue.
(E) Statistically signiﬁcant down-regulation of miR-17/20
expression in breast tumors over matching normal tissue.
P = 0.004 by Wilcoxon signed rank test. The grayscale intensity of each band in D was obtained by
AlphaImager software. The y axis value stands for the
addition of miR-17-5p and miR-20a expression in each
sample. (F) Signiﬁcant up-regulation of cyclin D1 expression in breast tumors over matching normal tissue.
P = 0.001. (G) Plotting the paired difference of tumor
and normal samples expression for each marker
(miR-17/20 vs. cyclin D1). The exact McNemar’s test
indicates a signiﬁcant association between the upregulation of expression in cyclin D1 and the downregulation of miR-17/20 expression. P = 0.002.

conducted. No significant difference in cyclin D1 mRNA levels
was observed between miR-17/20–transduced cells and control
cells (Fig. 4 A). This result suggests that the miR-17/20 cluster
regulates cyclin D1 gene expression at the posttranscriptional
level. Alignment of the human and mouse cyclin D1 mRNA 3⬘
UTRs identified a conserved miR-17/20–binding site (Fig. 4 B).
The miR-17/20–binding site (nucleotides 2,109–2,117) of human cyclin D1 is well conserved between species (Fig. 4 C).
To determine whether miR-17/20 directly regulates cyclin D1,
cyclin D1 mRNA 3⬘ UTR was linked to the firefly luciferase as
a reporter gene (Fig. 4 D). Full-length and cyclin D1 3⬘ UTR
fragments containing a wild-type or mutant miR-17/20–binding
site were inserted into the luciferase reporter vector (Fig. 4 D).
A construct without the miRNA binding sites was used as a negative control. When introduced into MCF-7 cells, the full-length
cyclin D1 3⬘ UTR reporter showed a 90% reduction in luciferase activity in the miR-17/20–transduced cells compared with
empty luciferase vector and negative control vector (Fig. 4 E).
The reporter vector carrying the cyclin D1 3⬘ UTR fragment
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with the miR-17/20 binding site showed reduced luciferase
activity in the transduced cells compared with control cells.
Mutation of the miR-17/20 binding site abrogated repression of
luciferase activity (Fig. 4 E).
Cyclin D1 is required for induction of
miR-17/20 expression

miR-17/20 can be induced by c-myc or E2F1, and miR-17/20 in
turn negatively regulates E2F1 translation (O’Donnell et al.,
2005; Sylvestre et al., 2007). c-myc, E2F, cyclin D1, and pRb
are important regulators of G0/G1–S transition of the cell cycle.
The miR-17/20 cluster is activated by c-myc in early G1, and the
E2F1 protein accumulates in late G1. Like c-myc, cyclin D1 is
activated early in the G1 phase. As c-myc is capable of inducing
miR-17/20, we examined the possibility that cyclin D1 may
also induce miR-17/20 expression. A retroviral expression vector
encoding cyclin D1 was used to transduce wild-type and cyclin
D1⫺/⫺ mouse embryonic fibroblasts (MEFs) to determine
whether cyclin D1 was sufficient to induce miR-17/20 expression.
Cyclin D1 overexpression was confirmed by Western blotting (Fig. S4, available at http://www.jcb.org/cgi/content/full/
jcb.200801079/DC1), and miRNA expression was confirmed by
Northern blotting (Fig. 5 A). miR-17-5p expression was reduced
to undetectable levels in cyclin D1⫺/⫺ cells (Fig. 5 A). Cyclin D1
transduction of cyclin D1⫺/⫺ cells resulted in physiological levels
of cyclin D1 and induced miR-17-5p and miR-20a expression
(Fig. 5 A, lanes 3 vs. 4). An unrelated miRNA, miR-100, showed
no difference in expression in cyclin D1⫺/⫺ cells by Northern
blotting (Fig. 5 A) and miRNA chip analysis (not depicted).
To determine whether miR-17-5p and cyclin D1 are coordinately regulated by physiological stimulation, MCF-7 cells
were serum-starved and then stimulated by 10% FBS. The time
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Figure 4. miR-17/20 represses cyclin D1
expression through a conserved 3ⴕ UTR site.
(A) Quantitative real-time RT-PCR assay did
not show signiﬁcant difference in mRNA level
of cyclin D1 between miR-17/20–transduced
cells and control cells. ABI1 was a positive
control. 18S served as an internal control for
normalization. This experiment was repeated
three times in triplicate. Data are mean ± SEM.
(B) BLASTN analysis of human and mouse
cyclin D1 mRNAs identiﬁed a miR-17-5p– and
miR-20a–binding site at the conserved 3⬘ UTR
region. (C) Sequence alignment of the miR-17-5p
and miR-20a base-paring site in the 3⬘ UTR of
cyclin D1 mRNAs. The region complementary
to the 2–10 nt of miR-17/20 is highly conserved among human, mouse, rat, and dog.
The “seed” sequence of miR-17/20 that is
complementary to cyclin D1 is shown in italics
and boxed. The mutant sequence is identical
to the wild-type sequence except the mutated
nucleotides are shown in red. (D) Luciferase reporter assay constructs. 3⬘ UTR FL, the full-length
3⬘ UTR of cyclin D1 inserted to the downstream
of the luciferase coding region in the pGL3
vector; 3⬘ UTR-1, a fragment of cyclin D1 3⬘
UTR containing the miR-17/20–binding sequence; 3⬘ UTR-1-mu, the mutated construct identical to 3⬘UTR-1 but point mutated in the miR-17/20 binding site;
3⬘ UTR-2, another fragment of cyclin D1 3⬘ UTR without the miR-17/20–binding sequence. (E) Luciferase reporter assay showed the decreased luciferase
activity in miR-17/20 overexpressed cells for both 3⬘ UTR FL and 3⬘ UTR-1 constructs, but not for the PGL-3 empty vector, 3⬘UTR-1-mu and 3⬘UTR-2
constructs. The luciferase activity was normalized to ␤-galactosidase. Data are derived from three independent experiments. Values are presented as the
mean ± SEM (n = 3). *, P < 0.01

course of cyclin D1 expression and miR-17-5p induction were
detected by Western and Northern blots, respectively (Fig. 5 B).
Cyclin D1 protein abundance was increased at 6 h, with maximal abundance at 12 h. miR-17-5p expression increased at 6 h
(Fig. 5 B). To determine whether cyclin D1 was required for serummediated induction of miR-17-5p, a comparison was made between cyclin D1⫺/⫺ and cyclin D1+/+ MEFs. The induction of
miR-17-5p by serum was identified in cyclin D1+/+ but not
cyclin D1⫺/⫺ MEFs (Fig. 5 C). To determine if cyclin D1 induced
miR-17/20 in vivo, MMTV-cyclin D1 transgenic mice were assessed. RNAs from MMTV–cyclin D1–induced mammary tumors,
and normal mouse mammary gland were compared and analyzed for miRNA expression using miRNA chips. Consistent
with the in vitro data, the miR-17/20 cluster was up-regulated in
the cyclin D1–induced mammary tumors (Fig. 5 D).
Cyclin D1 binds the promoter of the
miR-17/20 cluster

Cyclin D1 induced miR-17/20 expression, and cyclin D1 is
known to regulate gene transcription through occupancy of
a subset of gene promoters in the context of local chromatin, thereby regulating cellular differentiation and proliferation (Wang et al., 2003; Hulit et al., 2004; Fu et al., 2005).
Chromatin immunoprecipitation assays were performed to determine whether cyclin D1 occupied the miR-17/20 promoter
in the context of local chromatin in human breast epithelial
cells. MCF-10A cells were fixed, and a cell lysate was prepared.
Using a cyclin D1 antibody to immunoprecipitate cyclin D1–
binding DNAs, preimmune serum was used as negative control.
DNA was amplified by real-time PCR. 3 kb of the miR-17/20 cluster
upstream region was examined by 11 different pairs of primers,
which divide the miR-17/20 promoter region into 11 fragments
CYCLIN D1/MICRORNA 17/20 REGULATORY LOOP • Yu et al.
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(Fig. 5 E, fragments 1–11). A cyclin D1–specific binding site was
identified at fragment 5 (Fig. 5 E). Sequence analysis of this 139bp fragment identified multiple GC boxes upstream of fragment
5 and two TATA boxes downstream of fragment 5. Collectively,
these studies demonstrate that cyclin D1 binds to the miR-17/20
promoter and induces miR-17/20 expression at the transcriptional level.

Discussion
Several independent lines of evidence implicate miRNAs as either tumor suppressors or collaborative oncogenes (Calin et al.,
2004; Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006;
Zhang et al., 2007). miRNAs are differentially expressed in tumors, specific miRNAs are located within regions of chromosomal deletions or rearrangements in tumors, and miRNAs can
514
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Figure 5. Cyclin D1 induces miR-17-5p and miR-20a expression.
(A) Northern blotting showed the increased expression of miR-17-5p and
miR-20a in the MSCV–cyclin D1–infected MEF cells. miR-100 was used as
a negative control. tRNA served as loading control. (B) Breast cancer cell
line MCF-7. (C) cyclin D1⫺/⫺, and cyclin D1+/+ MEFs were starved by 5%
charcoal-stripped serum for 48 h, followed by 10% FBS stimulation. The
time course examination of the cyclin D1 protein level and the miR-17-5p
expression level were performed by Western and Northern blots, respectively.
The results showed the induction of cyclin D1 and miR-17-5p by serum
stimulation in the MCF-7 and cyclin D1+/+ MEF cells, but not in cyclin
D1⫺/⫺ MEFs. (D) miR-17-5p and miR-20a detection in the MMTV–cyclin D1
transgene induced mammary tumors (n = 3) compared with normal mice
mammary gland. Data from three mammary tumor samples were presented as mean ± SEM. (E) Real-time PCR analysis of cyclin D1 chromatin
immunoprecipitated DNA. 11 fragments derived from chromosome 11q31
upstream of miR-17/20 cluster were examined. For each fragment, ampliﬁcations on chromatin before immunoprecipitation and chromatin immunoprecipitated with preimmune serum were performed as input and negative
control, respectively. This experiment was repeated three times; data are
equal to mean ± SEM.

cooperate with oncogenes in tumorigenesis in animal models
(Croce and Calin, 2005). Importantly, the function of individual
miRNAs may be cell-type specific. The miR-17/20 cluster has
been found to function either as onco-miRNA or as a tumorsuppressor depending on the cell type (He et al., 2005; O’Donnell
et al., 2005; Hossain et al., 2006). Expression of the miR-17/20
cluster was increased by 65% in B cell lymphomas, and miR17/20 cooperates with c-Myc in lymphomagenesis (He et al.,
2005). In contrast, the miR-17/20 cluster inhibited proliferation
of the P493-6 cell line (O’Donnell et al., 2005). Herein, miR17/20 inhibited breast cancer cellular proliferation by repression
of cyclin D1 translation.
Our findings are of importance to the understanding of
breast tumorigenesis, as they directly link the miR-17/20 cluster
to the regulation of the cyclin D1 gene. Cyclin D1 plays a key
role in regulation of the G1–S phase transition and in tumorigenesis (Fu et al., 2004). The abundance of cyclin D1 is induced by
a broad array of oncogenic stimuli and is required for contactindependent growth (Albanese et al., 1995; Fu et al., 2004).
Cyclin D1 is required for ErbB2-induced mammary tumorigenesis in vivo (Lee et al., 2000; Yu et al., 2001). Herein, an inverse
correlation was found between miR-17/20 and cyclin D1 in human
breast cancer samples, in breast cancer cell lines, and in transgenic
mice. Our finding that miRNA regulate breast cancer cellular
proliferation and contact-independent growth is consistent with
recent findings that specific miRNA can regulate breast cancer
progression. miR-126 reduces breast tumor growth (Tavazoie
et al., 2008), miR-335 inhibits breast cancer metastasis (Tavazoie
et al., 2008), and miR-373 and miR-520c stimulate breast cancer
cell migration and invasion by suppressing the metastasis suppressor gene CD44 (Huang et al., 2008). The current studies
provide evidence for an additional level of fine control in regulation of the G1–S phase transition of the cell cycle. The inhibition of DNA synthesis by miR-17/20 was associated with a
reduction in the proportion of cells in the S phase and an increased proportion of cells in G1 phase. Cyclin E, which, like
cyclin D1, is capable of enhancing G1–S phase transition in
MCF-7 cells, was not regulated by miR-17/20. As the abundance
of cyclin D1 is rate-limiting in MCF7 cell growth and G1–S
phase progression (Fu et al., 2004), the inhibition of cyclin D1
expression by miR-17/20 likely contributes to the inhibition of
DNA synthesis and cellular proliferation in breast cancer cells.
Both cyclin D1 and c-myc are activated early in the G1
phase and are key regulators of the G1–S phase transition.
Cyclin D1 activates E2F1 transactivation through phosphorylation of pRb. E2F1 expression is induced by c-myc (Matsumura
et al., 2003). miR-17-5p and miR-20a limit c-myc–mediated induction of E2F1 translation (O’Donnell et al., 2005), providing
a mechanism to dampen reciprocal activation of c-myc to E2F1.
Our studies provide evidence for a novel level of fine tuning to
regulate the functional interactions between cyclin D1, c-myc, E2F,
and miRNAs. Cyclin D1 abundance is increased in ⵑ50% of
human breast cancers. The cyclin D1 gene encodes the labile
catalytic subunit of the holoenzyme that phosphorylates and
inactivates the pRb protein. The pRb protein serves as a paradigmatic tumor suppressor. The current studies are the first to
demonstrate that cyclin D1 abundance is controlled by miRNA.
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D1 in mammary gland–targeted cyclin D1 transgene-induced
breast tumors. Thus, the phenotype of cellular growth may be
determined by the ability of cyclin D1 to evade translational
attenuation by miR-17/20.

Materials and methods

Figure 6. miR-17/20 regulatory loops. (A) E2F-miR-17/20 regulatory
loop. (B) AML1-miR-17/20 regulatory loop. (C) c-Myc–miR-17/20 regulatory
loop. (D) cyclin D1–miR-17/20 regulatory loop. Red arrows are supported
by our data. Black arrows are supported by scientiﬁc literature.
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The binding site identified within the cyclin D1 3⬘ UTR required
for repression by miR-17/20 is highly conserved between species.
As the relative abundance of cyclin D1 is tightly regulated, multiple
distinct mechanisms are involved to control cyclin D1 abundance,
including transcriptional induction, posttranslational regulation, and in the current studies, posttranscriptional regulation
via miRNA.
The studies herein provide genetic evidence that cyclin D1
binds to an miRNA promoter and regulates a specific miRNA
signature. Genetic knockout of cyclin D1 or siRNA treatment
demonstrated that the miR-17/20 cluster is induced by cyclin D1.
Mammary gland–targeted cyclin D1 expression recapitulated this
miRNA signature in the mammary gland tumor. In previous
studies, cyclin D1 was identified within chromatin of target endogenous gene promoters in the context of nuclear receptor binding
sites (peroxisome proliferator–activated receptor ␥) and AP-1/
CRE sites (Fu et al., 2005; Wang et al., 2003). Herein, cyclin D1
was identified within the miR-17/20 promoter in the context of
local chromatin using chromatin immunoprecipitation assays,
extending the potential mechanisms by which cyclin D1 may
regulate other miRNAs.
Previous studies have demonstrated the induction of miR17/20 by c-myc and E2F (O’Donnell et al., 2005; Sylvestre et al.,
2007). The E2F family is negatively regulated by miR-17/20
(O’Donnell et al., 2005; Sylvestre et al., 2007). We examined
the abundance of c-myc in miR-17/20–overexpressed cells and
found the repression of c-myc by miR-17-5p (Fig. S5, available at
http://www.jcb.org/cgi/content/full/jcb.200801079/DC1). Thus,
four key regulatory proteins—c-Myc, E2F1, AML1 (O’Donnell
et al., 2005; Fontana et al., 2007; Sylvestre et al., 2007), and cyclin
D1—converge on the miR-17/20 cluster promoter region to create important regulatory feedback loops (Fig. 6). Consistent
with this model, translation of the cyclin D1–binding protein
AIB1 is repressed by miR-17/20 (Hossain et al., 2006). In turn,
miR-17-15p/miR-20a attenuates this activity by inhibiting each
of these upstream activators. These attenuating feedback loops
provide mechanisms to tightly control proliferative signals.
Herein, the expression of miR-17/20 was increased by cyclin

Mice and human breast samples
All animal experiments were done in accordance with the guidelines for
the care and use of laboratory animals at Thomas Jefferson University.
Cyclin D1⫺/⫺ mice were maintained on a mixed C57B1/6 × 129/SvJ background as described previously (Hulit et al., 2004). Genotyping was done
on tail DNA by PCR as described previously (Hulit et al., 2004). Cyclin D1
transgenic mice were made and maintained as described previously
(Wang et al., 1994). MMTV–cyclin D1 transgenic mice were obtained
from A. Arnold (University of Connecticut, Farmington, CT). Human breast
cancer specimens and matching normal breast tissue samples were provided by P. McCue (Thomas Jefferson Hospital, Philadelphia, PA). All the
procedures were approved by the Institutional Review Board of Thomas
Jefferson University. Expression for miR-17/20 and cyclin D1 in paired tumor
and normal samples were analyzed for signiﬁcant up- or down-regulation
using the Wilcoxon signed rank test. The association of down-regulation in
miRNA expression and up-regulation in cyclin D1 expression was completed
via the exact McNemar’s test. AlphaImager (Alpha Innotech) was used for
intensity analysis.
Vectors
miR-17/20 expression vector was provided by J. Mendell (Johns Hopkins
University School of Medicine, Baltimore, MD) and A. Thomas-Tikhonenko
(University of Pennsylvania, Philadelphia, PA). Human cyclin D1 cDNAs were
cloned into the mouse stem cell virus (MSCV)-internal ribosome entry site
(IRES)-GFP retrovirus vector at the EcoRI site. Different lengths of wild-type and
mutated cyclin D1 3⬘ UTR sequences were inserted into the XbaI–FseI site immediately downstream of the stop codon in the pGL3 ﬁreﬂy luciferase reporter vector. pMSCVpuro vector was used to express miR-17/20 cluster at the
EcoRI site as described previously (O’Donnell et al., 2005). A recombinant
plasmid that carries the bacterial ␤-galactosidase cDNA driven by the CMV
promoter was used as an internal control for transfection efﬁciency.
Oligonucleotides
All DNA probes were synthesized by Integrated DNA Technologies. Primer
sequences for cyclin D1 3⬘ UTR cloning were as follows: 3⬘ UTR FL forward, 5⬘-GGGCGCCAGGCAG-3⬘; 3⬘ UTR FL reverse, 5⬘-ACAGGACAGACT-3⬘; 3⬘ UTR-1 forward, 5⬘-ACCATCCAGTGGAGG-3⬘; 3⬘ UTR-1
reverse, 5⬘-TGGCAATGTGAGAAT-3⬘; 3⬘ UTR-2 forward, 5⬘-GCCGCAGCTCCATT-3⬘; and 3⬘ UTR-2 reverse, 5⬘-ATGGCTAAGAGAA-3⬘. The probe
sequences for miRNA northern analysis were as follows: miR-17-5p, 5-ACTACCTGCACTGTAAGCACTTTG-3⬘; miR-18a, 5⬘-TATCTGCACTAGATGCACCTTA-3⬘; miR-19a, 5⬘-TCAGTTTTGCATAGATTTGCACA-3⬘; miR-19b, 5⬘-TCAGTTTTGCATGGATTTGCACA-3⬘; miR-20a, 5⬘-CTACCTGCACTATAAAGCACTTTA-3⬘; miR-92, 5⬘-ACAGGCCGGGGACAAGTGCAATA-3⬘, and miR-100,
5⬘- CACAAGTTCGGATCTACGGGTT-3⬘. siRNAs were obtained from QIAGEN. Target sequence for cyclin D1: 5⬘-AACAAGCTCAAGTGGAACCTG-3⬘;
target sequence for negative control siRNA: 5⬘-AATTCTCCGAACGTGTCACGT-3⬘. Anti-miR miRNA inhibitors are chemically modiﬁed, single-stranded
nucleic acids antisense to target miRNAs. Anti–miR-17, anti–miR-20, and
negative controls were obtained from Ambion.
Cell culture
Cyclin D1+/+ and cyclin D1⫺/⫺ primary MEFs were prepared as described
previously (Wang et al., 2003). MCF-10A cells were cultured in DME/F12
medium containing 5% horse serum, 10 μg/ml insulin, 20 ng/ml EGF, 100
ng/ml choleratoxin, 0.5 μg/ml hydrocortisone, and 100 mg/liter of penicillin and streptomycin. 293T, Hela, MCF-7, Hs578T, T47D, BT474, SKBR-3,
MDA-MB-231, MDA-MB-361, MDA-MB-453, MDA-MB-486, and the
NAFA cell line derived from the MMTV-NeuT mouse cells were cultured in
DME containing penicillin and streptomycin (100 mg of each per liter) and
supplemented with 10% FBS.
Retrovirus infection, siRNA/plasmid transfection, and luciferase
reporter assay
Retroviral production and infection methods have been described previously in detail (Li et al., 2006). The ecotropic packaging vector pSV-⌿–E-MLV,
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which provides ecotropic packaging helper function, was used with retrovirus to infect cells. For cellular transfection with plasmid DNA, actively
growing cells were seeded on 12-well plates at a density of 1 × 105 cells per
well in an antibiotic-free medium. The next day, cells were cotransfected
using Lipofectamine 2000 (Invitrogen) with 0.5 μg of pGL3 and 0.1 μg of
CMV/␤-galactosidase plasmid. 24 h after transfection, luciferase activities
were measured by AutoLumat (Berthold Technologies) and normalized with
␤- galactosidase. For the reverse transfection of siRNA to MCF-7 cells, Lipofectamine RNAiMAX was used according to the manufacturer’s instructions (Invitrogen).
miRNA expression proﬁling and data analysis
miRNA expression arrays were generated at Kimmel Cancer Center at
Thomas Jefferson University and probed essentially as described previously
(Liu et al., 2004). In brief, 5 μg of total RNA from each sample was biotinlabeled during reverse transcription using random hexanes. Hybridization
was performed on an miRNA microarray chip that contained 368 probes
in triplicate, corresponding to 245 human and mouse miRNA genes.
All probes on these microarrays were 40-mer oligonucleotides spotted by
contacting technologies and covalently attached to a polymeric matrix.
Hybridization signals were detected by biotin binding of a Streptavidin–
Alexa 647 conjugate using a ScanArray XL5K (PerkinElmer). Scanner images were quantiﬁed by the Quantarray software (PerkinElmer). Signal
intensities were normalized and analyzed using GeneSpring software
(Agilent Technologies).

Real time RT-PCR analysis
Total RNA was extracted with Trizol reagent (Invitrogen). The 7900 HT Sequence Detection System (Applied Biosystems) was used for quantitative RTPCR assay. Primers were designed using primer Express 1.5/Taqman Primer
Design software (Applied Biosystems). The primer sequences were as follows: cyclin D1 forward, 5⬘-AAGCTGTGCATCTACACCGA-3⬘; cyclin D1
reverse, 5⬘-CTTGAGCTTGTTCACCAGGA-3⬘; AIB-1 forward, 5⬘-AAACTCCATGGGAAGACCAG-3⬘; AIB-1 reverse, 5⬘-GTCTCGCACCTGGTATGCTA-3⬘;
18S forward, 5⬘-CTACCACATCCAAGGAAGGCA-3⬘; and 18S reverse,
5⬘-TTTTTCGTCACTACCTCCCCG-3⬘.
Western blot analysis
Whole-cell lysates (50 μg) were separated by 10% SDS-PAGE, and the proteins were transferred to nitrocellulose membrane. The following antibodies
were used for Western blotting: anti–cyclin D1 (Thermo Fisher Scientiﬁc),
anti-AIB1 (BD Biosciences), anti-GDI (RTG Solutions), and anti-Myc (sc-40)
and anti–␤-tubulin (sc-9104; both from Santa Cruz Biotechnology, Inc.).
Cell proliferation assays
Cells were infected with pMSCVpuro-miR-17/20 cluster or pMSCVpuro empty
vector. After puromycin selection, 4 × 104 cells per milliliter were seeded into
6-well plate in triplicate, and the cell number was counted every day for 3–4 d
under microscope using a hemocytometer. For the 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium (MTT) assay, 4 × 103 cells per well were seeded
into a 96-well plate in triplicate, and after a 24-h culture, the cell growth
was measured by MTT bromide assay.
Colony formation assay
The same amount of miR-17/20 overexpression MCF-7 cells and control cells
were plated in triplicate in a 6-well plate in puromycin-containing medium.
After incubation at 37°C for 7–10 d, the colonies were stained with Crystal
Violet solution (Allied Chemical Corporation) in methanol for 15–30 min.
Colonies >50 μm in diameter were counted.
Cell cycle analysis
Cells were starved in DME supplemented with 5% charcoal-stripped serum.
After 48 h, medium was changed with DME with 10% normal FBS. Cells
were harvested at different time points, and cell cycle parameters were
determined using laser scanning cytometry. Cells were processed by
standard methods by using propidium iodide staining of cell DNA. 10,000
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Chromatin immunoprecipitation
MCF-10A cells were cross-linked with formaldehyde (ﬁnal concentration of
1%), and chromatin immunoprecipitation was performed as described previously (Weinmann et al., 2001) using anti–cyclin D1 antibody (SC-450;
Santa Cruz Biotechnology, Inc.). Real-time PCR was performed using the
SYBR green PCR Master Mix kit (Applied Biosystems) to amplify the
immunoprecipitated DNA. Sequences of primers derived from the genomic
region upstream of the miR-17/20 cluster are provided in Table S1 (available at http://www.jcb.org/cgi/content/full/jcb.200801079/DC1).
Online supplemental material
Fig. S1 shows the low miR-17-5p and miR-20a expression in human breast
cancer cell lines. Fig. S2 shows the cell cycle analysis of miR-17/20–transduced MCF-10A and BT474 cells. Fig. S3 shows that inhibition of endogenous miR-17/20 by anti–miR-17-5p and anti–miR-20a increased cyclin
D1 expression in MCF-7 cells. Fig. S4 shows overexpression of cyclin D1
in the MSCV–cyclin D1–transduced cyclin D1⫺/⫺ MEFs. Fig. S5 shows the
inhibition of c-myc expression by the miR-17/20 cluster in MCF-7 cells.
Table S1 shows primer sequences for real-time PCR ampliﬁcation of cyclin
D1 chromatin immunoprecipitation assay. Online supplemental material is
available at http://www.jcb.org/cgi/content/full/jcb.200801079/DC1.
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